title: The role of transcription factors in prostate cancer and potential for future RNA interference therapy.
abstract: BACKGROUND
  Prostate cancer is a leading cause of cancer-related death in men and current treatments offer only a modest survival benefit in advanced stages of the disease. RNA interference (RNAi) is a therapeutic option that has received great attention in recent years with the potential to treat a variety of disorders, including prostate cancer. Transcription factors are cellular proteins that can up-regulate or down-regulate the transcription of genes and offer promising therapeutic targets.
  
  
  METHODS
  This review will focus on transcription factors that have been identified as key molecules in drug resistance, disease progression and metastases in prostate cancer, which may offer potential as therapeutic targets for RNAi in the future.
  
  
  CONCLUSIONS
  By identifying therapeutically viable transcription factor targets in prostate cancer, it is hoped that treatment strategies using RNAi will augment the effect of current chemotherapy regimens, slow disease progression and reduce metastases in prostate cancer, resulting in disease regression.
authors.affiliation: PhD student in gene delivery, University College Cork, School of Pharmacy, Cavanagh Pharmacy Building , Cork , Ireland.
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Fitzgerald
authors.forename: James C
authors.initials: JC
authors.lastname: Evans
authors.forename: Joanna
authors.initials: J
authors.lastname: McCarthy
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Guo
authors.forename: Maria
authors.initials: M
authors.lastname: Prencipe
authors.forename: Meghan
authors.initials: M
authors.lastname: Kearney
authors.forename: William R
authors.initials: WR
authors.lastname: Watson
authors.forename: Caitriona M
authors.initials: CM
authors.lastname: O'Driscoll
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000072278:Forkhead Box Protein M1; D051858:Forkhead Transcription Factors / Q000502:physiology; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000628:therapy*; D034622:RNA Interference; D011944:Receptors, Androgen / Q000502:physiology; D050791:STAT Transcription Factors / Q000502:physiology; D026362:Serum Response Factor / Q000502:physiology; D018808:Transcription Factor AP-1 / Q000502:physiology; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*
chemical_list: D000726:Androgen Antagonists; C107585:FOXM1 protein, human; D000072278:Forkhead Box Protein M1; D051858:Forkhead Transcription Factors; D016328:NF-kappa B; D011944:Receptors, Androgen; D050791:STAT Transcription Factors; D026362:Serum Response Factor; D018808:Transcription Factor AP-1; D014157:Transcription Factors
keywords: RNA interference; Y-box-binding protein-1; activator protein-1; androgen receptor; delivery of RNAi; eIF4E; forkhead box M1; gene therapy; nuclear factor κ B; prostate cancer; serum response factor; signal transducer and activator of transcription; specificity protein 1; transcription factor